10 May 2007 - Epigenomics AG has entered into an R&D collaboration with Myriad Genetics, Inc. to identify and analyze DNA methylation biomarkers that may predict patients' response to an undisclosed marketed oncology drug.
Under the agreement, Epigenomics will use its proprietary Differential Methylation Hybridization (DMH) microarray platform to perform genome-wide DNA methylation profiling on samples provided by Myriad and compare these profiles to identify DNA methylation biomarkers associated with sensitivity and resistance to the drug.
Epigenomics will also apply its OncoSign(TM) approach that is offered in collaboration with its partner CellTrend GmbH for fast track identification of DNA methylation biomarkers for the drug in an established panel of human tumor cell lines. Financial details were not disclosed.
 |
www.bionity.com/news/e/64517 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/64517 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |